

# Kosh Agarwal

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4671890/kosh-agarwal-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

237  
papers

18,365  
citations

52  
h-index

134  
g-index

294  
ext. papers

22,260  
ext. citations

8.6  
avg, IF

6.75  
L-index

#	Paper	IF	Citations
237	Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels.. <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	6
236	A case of HBV-induced liver failure in the REEF-2 Phase 2 trial: Implications for finite treatment strategies in HBV 'cure'.. <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	5
235	Global elimination of hepatitis C: a warning from the data.. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2022</b> , 7, 380-381	18.8	0
234	The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet, The</i> , <b>2021</b> ,	40	12
233	Real-World Outcomes of DAA Treatment and Retreatment in UK-based Patients Infected with HCV Genotypes/Subtypes Endemic in Africa. <i>Journal of Infectious Diseases</i> , <b>2021</b> ,	7	2
232	Mitochondrial dysfunction as a mechanistic biomarker in patients with non-alcoholic fatty liver disease (NAFLD). <i>Mitochondrion</i> , <b>2021</b> , 57, 119-130	4.9	10
231	Patterns and prediction of liver injury with persistent cholestasis in survivors of severe SARS-CoV-2 infection. <i>Journal of Infection</i> , <b>2021</b> , 82, e11-e13	18.9	2
230	Hepatitis B cure: How and when. <i>Liver International</i> , <b>2021</b> , 41 Suppl 1, 24-29	7.9	2
229	A Very Short Course of HBIg+NA Followed by Entecavir or Tenofovir Monotherapy Prevents HBV Recurrence in Low-Risk Liver Transplant Recipients. <i>Transplantation Proceedings</i> , <b>2021</b> , 53, 207-214	1.1	0
228	Risk stratification in chronic hepatitis B patients for hepatocellular carcinoma surveillance: management in migrant sub-Saharan African populations. <i>Gut</i> , <b>2021</b> , 70, 629-630	19.2	1
227	Mitochondrial metabolic manipulation by SARS-CoV-2 in peripheral blood mononuclear cells of patients with COVID-19. <i>American Journal of Physiology - Cell Physiology</i> , <b>2021</b> , 320, C57-C65	5.4	51
226	Circulating Pregenomic Hepatitis B Virus RNA Is Primarily Full-length in Chronic Hepatitis B Patients Undergoing Nucleos(t)ide Analogue Therapy. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, 2029-2031	11.6	7
225	Impact of direct-acting antiviral agents on liver function in patients with chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 168-176	3.4	1
224	The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 12-19	3.4	12
223	Severe alcohol-related liver disease admissions post-COVID-19 lockdown: canary in the coal mine?. <i>Frontline Gastroenterology</i> , <b>2021</b> , 12, 354-355	2.6	6
222	Reply. <i>Hepatology</i> , <b>2021</b> , 73, 870-871	11.2	
221	Current Management of Patients with HCV Genotype 5 or 6 <b>2021</b> , 129-140		

220	A novel microRNA-based prognostic model outperforms standard prognostic models in patients with acetaminophen-induced acute liver failure. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 424-434	13.4	5
219	Unmet Needs in Clinical Research Hepatitis B <b>2021</b> , 51-71		
218	Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> ,	6.9	17
217	Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. <i>Clinical Microbiology Reviews</i> , <b>2020</b> , 33,	34	82
216	Sequential Cohort Analysis After Liver Transplantation Shows de Novo Extended Release Tacrolimus Is Safe, Efficacious, and Minimizes Renal Dysfunction. <i>Transplantation Direct</i> , <b>2020</b> , 6, e528	2.3	
215	Successful liver transplantation for drug-induced vanishing bile duct syndrome. <i>BMJ Case Reports</i> , <b>2020</b> , 13,	0.9	4
214	Will we need novel combinations to cure HBV infection?. <i>Liver International</i> , <b>2020</b> , 40 Suppl 1, 35-42	7.9	5
213	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 441-453	18.8	45
212	Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 1097-1104	13.4	9
211	Serum MicroRNA Signatures in Recovery From Acute and Chronic Liver Injury and Selection for Liver Transplantation. <i>Liver Transplantation</i> , <b>2020</b> , 26, 811-822	4.5	7
210	English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 168-181	6.1	2
209	Differential effect of interferon-alpha treatment on AEA and 2-AG levels. <i>Brain, Behavior, and Immunity</i> , <b>2020</b> , 90, 248-258	16.6	4
208	Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 152-166	18.8	49
207	Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy. <i>Hepatology</i> , <b>2020</b> , 72, 42-57	11.2	46
206	Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B. <i>Hepatology Communications</i> , <b>2020</b> , 4, 8-20	6	18
205	Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 431-440	13.4	13
204	Reply to: "Is resistance to direct-acting antivirals in sub-Saharan Africa a threat to HCV elimination? Recommendations for action". <i>Journal of Hepatology</i> , <b>2020</b> , 72, 585-586	13.4	0
203	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 539-557	13.4	88

202	Hepatitis B in sub-Saharan Africa-How many patients need therapy?. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 560-567	3.4	6
201	EASL Recognition Award Recipient 2020: Prof. Patrick Marcellin. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 482-483	3.4	
200	The Role of RNA Interference in Functional Cure Strategies for Chronic Hepatitis B. <i>Current Hepatology Reports</i> , <b>2020</b> , 19, 362-369	1	4
199	EASL recommendations on treatment of hepatitis C: Final update of the series. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1170-1218	13.4	237
198	FRI-159-Can HBcrAg and pre-genomic HBV RNA predict the risk of ALT flares after nucleoside analogue therapy withdrawal: delineating the clinical utility of new biomarkers?. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e458	13.4	3
197	Strain elastography for noninvasive assessment of liver fibrosis: A prospective study with histological comparison. <i>Ultrasound</i> , <b>2019</b> , 27, 262-271	1.3	2
196	PS-055-The markers of HBV transcriptional activity-HBcrAg and pre-genomic HBV DNA during antiviral therapy with nucleos (t)ide analogue help to predict optimal timing of therapy withdrawal. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e33-e34	13.4	2
195	The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. <i>Hepatology</i> , <b>2019</b> , 70, 788-801	11.2	101
194	Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication. <i>Liver International</i> , <b>2019</b> , 39, 1837-1844	7.9	8
193	The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 204-214	6.1	11
192	Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 660-665	13.4	50
191	LBO-06-Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e130	13.4	18
190	Reactivation of hepatitis B virus infection in patients with hematologic disorders. <i>Haematologica</i> , <b>2019</b> , 104, 435-443	6.6	20
189	Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 1099-1105	13.4	36
188	Antiviral treatment for hepatitis C: rebalancing cost, affordability, and availability. <i>The Lancet Global Health</i> , <b>2019</b> , 7, e1150-e1151	13.6	2
187	Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients. <i>Scientific Reports</i> , <b>2019</b> , 9, 10529	4.9	7
186	Hepatitis B virus infection in children and adolescents. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 466-476	18.8	62
185	Hepatitis C virus infection in children and adolescents. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 477-487	18.8	69

184	Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group. <i>Journal of Infection</i> , <b>2019</b> , 79, 503-512	18.9	12
183	PS-181-Unacceptably low SVR rates in African patients with unusual HCV sub-genotypes : Implications for global elimination. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e111-e112	13.4	3
182	PS-178-Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e110	13.4	2
181	Interferon lambda 4 impacts the genetic diversity of hepatitis C virus. <i>ELife</i> , <b>2019</b> , 8,	8.9	17
180	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Hepatology</i> , <b>2019</b> , 71, 1070	11.2	23
179	Hepatitis C: Treatment <b>2019</b> , 454-469		
178	Advancing Age and Comorbidity in a US Insured Population-Based Cohort of Patients With Chronic Hepatitis B. <i>Hepatology</i> , <b>2019</b> , 69, 959-973	11.2	33
177	Persistent fatigue induced by interferon-alpha: a novel, inflammation-based, proxy model of chronic fatigue syndrome. <i>Psychoneuroendocrinology</i> , <b>2019</b> , 100, 276-285	5	31
176	Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 337-349	3.4	24
175	Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease. <i>Kidney International Reports</i> , <b>2019</b> , 4, 257-266	4.1	7
174	Liver transplant listing for hepatitis C-associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct-acting antiviral therapy. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 231-235	3.4	14
173	Case finding and therapy for chronic viral hepatitis in primary care (HepFREE): a cluster-randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 32-44	18.8	12
172	Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 24-32	13.4	17
171	Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial. <i>Hepatology</i> , <b>2018</b> , 67, 2113-2126	11.2	18
170	Reducing the Number of Measurements in Liver Point Shear-Wave Elastography: Factors that Influence the Number and Reliability of Measurements in Assessment of Liver Fibrosis in Clinical Practice. <i>Radiology</i> , <b>2018</b> , 287, 844-852	20.5	23
169	Serum NGAL can act as an early renal safety biomarker during long-term nucleos(t)ide analogue antiviral therapy in chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 1139-1150	3.4	1
168	Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. <i>Hepatology</i> , <b>2018</b> , 68, 1298-1307	11.2	121
167	Current and future directions of management of hepatitis B: steps toward a cure. <i>Future Virology</i> , <b>2018</b> , 13, 189-209	2.4	1

166	EASL Recommendations on Treatment of Hepatitis C 2018. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 461-511	13.4	1079
165	96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 672-681	13.4	180
164	Reply to: "Reply to: 'Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries'". <i>Journal of Hepatology</i> , <b>2018</b> , 68, 864-866	13.4	2
163	Interferon-free direct-acting antiviral therapy for acute hepatitis C virus infection in HIV-infected individuals: A literature review. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 113-123	3.3	5
162	Palliative care in end-stage liver disease: Time to do better?. <i>Liver Transplantation</i> , <b>2018</b> , 24, 961-968	4.5	19
161	Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 944-953	3.3	21
160	Effects of Treatment of Chronic Hepatitis B Virus Infection on Patient-Reported Outcomes. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 1641-1649.e6	6.9	16
159	Delineating the global challenges of hepatitis B virus infection. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 372-373	18.8	5
158	Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 224-225	18.8	1
157	HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 886-893	3.4	23
156	A183 SOFOSBUVIR-BASED ALL-ORAL REGIMENS FOR PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 3 INFECTION: INTEGRATED ANALYSIS OF FIVE CLINICAL STUDIES. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2018</b> , 1, 318-319	0.5	78
155	Depression and anxiety in patients receiving interferon-alpha: The role of illness perceptions. <i>Journal of Health Psychology</i> , <b>2018</b> , 23, 1405-1414	3.1	10
154	Management of chronic hepatitis B before and after liver transplantation. <i>Frontline Gastroenterology</i> , <b>2018</b> , 9, 79-84	2.6	6
153	Can quantitative hepatitis B surface antigen levels predict the severity of liver disease in genotype E Patients?. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 80-87	3.4	4
152	Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 417-426	6.9	159
151	Dolutegravir-induced liver injury leading to sub-acute liver failure requiring transplantation: a case report and review of literature. <i>International Journal of STD and AIDS</i> , <b>2018</b> , 29, 414-417	1.4	15
150	Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III). <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 118-125	3.4	8
149	Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial. <i>Hepatology</i> , <b>2018</b> , 67, 514-523	11.2	96



148	Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence. <i>Therapeutic Advances in Gastroenterology</i> , <b>2018</b> , 11, 1756284818786108	4.7	15
147	Long-term follow-up of patients with chronic HCV infection and compensated or decompensated cirrhosis following treatment with sofosbuvir-based regimens. <i>Journal of Hepatology</i> , <b>2018</b> , 68, S67-S68	13.4	8
146	Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 1331-1340	3.4	41
145	Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 603-607	13.4	44
144	Hepatitis C and bleeding disorders in Europe. <i>The Journal of Haemophilia Practice</i> , <b>2018</b> , 5, 50-65	0.2	
143	Eliminating hepatitis C within low-income countries - The need to cure genotypes 4, 5, 6. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 814-826	13.4	28
142	A180 IMPROVED RENAL LABORATORY PARAMETERS IN CHB PATIENTS TREATED WITH TAF COMPARED WITH TDF. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2018</b> , 1, 313-314	0.5	78
141	The role of anti-HBs in hepatitis B reactivation during direct-acting antiviral therapy for chronic hepatitis C. <i>Antiviral Therapy</i> , <b>2018</b> , 23, 539-542	1.6	3
140	Efficacy and Tolerability of Direct-Acting Antivirals for Hepatitis C in Older Adults. <i>Journal of the American Geriatrics Society</i> , <b>2018</b> , 66, 1339-1345	5.6	6
139	The road map toward an hepatitis C virus-free transplant population. <i>American Journal of Transplantation</i> , <b>2018</b> , 18, 2409-2416	8.7	2
138	The impact of antiviral therapy for hepatitis C on the quality of life: a perspective. <i>Liver International</i> , <b>2017</b> , 37 Suppl 1, 7-12	7.9	20
137	Cirrhosis and liver transplantation in patients co-infected with HIV and hepatitis B or C: an observational cohort study. <i>Infection</i> , <b>2017</b> , 45, 215-220	5.8	7
136	Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. <i>Gastroenterology</i> , <b>2017</b> , 153, 113-122	13.3	180
135	Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 263-271	13.4	218
134	EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 370-398	13.4	2354
133	Improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: preliminary results from 2 phase 3 studies in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2017</b> , 66, S25	13.4	12
132	International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. <i>Transplantation</i> , <b>2017</b> , 101, 945-955	1.8	63
131	International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. <i>Transplantation</i> , <b>2017</b> , 101, 956-967	1.8	40

130	Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 224-236	13.4	90
129	Hepatitis C in the EU: setting the terms for elimination. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 314-315	18.8	2
128	Diagnosing liver fibrosis: a narrative review of current literature for dermatologists. <i>British Journal of Dermatology</i> , <b>2017</b> , 177, 637-644	4	5
127	Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review. <i>BMC Infectious Diseases</i> , <b>2017</b> , 17, 722	4	24
126	Treatment of Genotype 3 Chronic Hepatitis C Virus Infection. <i>Clinical Medicine Insights Therapeutics</i> , <b>2017</b> , 9, 1179559X1769433	0	
125	Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank. <i>International Journal of Epidemiology</i> , <b>2017</b> , 46, 1391-1391h	7.8	17
124	Direct-acting antiviral therapy in patients with hepatocellular cancer: The timing of treatment is everything. <i>Journal of Hepatology</i> , <b>2017</b> ,	13.4	6
123	A phase 2a study evaluating the multi-dose activity of ARB-1467 in HBeAg positive and negative virally suppressed subjects with hepatitis B. <i>Journal of Hepatology</i> , <b>2017</b> , 66, S688-S689	13.4	18
122	Elbasvir/Grazoprevir Plus Sofosbuvir in Treatment-Naive and Treatment-Experienced Cirrhotic Patients with Hepatitis C Virus Genotype 3 Infection Treated for 8, 12 or 16 Weeks: Final Results of the C-ISLE Study. <i>Gastroenterology</i> , <b>2017</b> , 152, S1061	13.3	3
121	Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 805-813	18.8	15
120	Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 1348-1350	13.4	20
119	Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 900-909	18.8	129
118	Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 910-919	18.8	57
117	MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1B infection. <i>Journal of Hepatology</i> , <b>2017</b> , 66, S90-S91	13.4	47
116	Immunological Predictors of Nonresponse to Directly Acting Antiviral Therapy in Patients With Chronic Hepatitis C and Decompensated Cirrhosis. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, ofx067	1	11
115	Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant. <i>Annals of Hepatology</i> , <b>2017</b> , 16, 375-381	3.1	5
114	Impact of comorbidity on waiting list and post-transplant outcomes in patients undergoing liver retransplantation. <i>World Journal of Hepatology</i> , <b>2017</b> , 9, 884-895	3.4	6
113	Developing a donation after cardiac death risk index for adult and pediatric liver transplantation. <i>World Journal of Transplantation</i> , <b>2017</b> , 7, 203-212	2.3	40



112	Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant. <i>Annals of Hepatology</i> , <b>2017</b> , 16, 375-381	3.1	
111	High Efficacy of an 8-Week 3-Drug Regimen of Grazoprevir/MK-8408/MK-3682 in HCV Genotype 1, 2 and 3-Infected Patients: SVR24 Data from the Phase 2 C-Crest 1 and 2 Studies. <i>Journal of Hepatology</i> , <b>2016</b> , 64, S759	13.4	6
110	PWE-037 Reliability of Arfi Shear Velocity Cut-Off for Diagnosis of Cirrhosis in Chronic Hepatitis C: A "Real World" Two Centre Simultaneous Biopsy-Controlled Study in The UK. <i>Gut</i> , <b>2016</b> , 65, A157.1-A157 <sup>19.2</sup>		
109	Pregnancy and liver disease. <i>Journal of Hepatology</i> , <b>2016</b> , 64, 933-45	13.4	131
108	Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Infectious Diseases, The</i> , <b>2016</b> , 16, 685-697	25.5	346
107	Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. <i>Journal of Hepatology</i> , <b>2016</b> , 64, 1224-31	13.4	344
106	Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 33-39	13.4	86
105	PTH-107 Chronic Hepatitis B Management The UK: A National Survey of Current Practice Following Nice Guidance. <i>Gut</i> , <b>2016</b> , 65, A271.2-A272	19.2	
104	Liver Retransplantation in Patients With HIV-1 Infection: An International Multicenter Cohort Study. <i>American Journal of Transplantation</i> , <b>2016</b> , 16, 679-87	8.7	7
103	Concentration Monitoring of Plasma Ribavirin: Validation of a Liquid Chromatography-Mass Spectrometric Method and Clinical Sample Collection. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 50-8	3.2	3
102	Does Donation After Cardiac Death Utilization Adversely Affect Hepatocellular Cancer Survival?. <i>Transplantation</i> , <b>2016</b> , 100, 1916-24	1.8	21
101	Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 741-747	13.4	278
100	Transcriptomics in Interferon- $\alpha$ -Treated Patients Identifies Inflammation-, Neuroplasticity- and Oxidative Stress-Related Signatures as Predictors and Correlates of Depression. <i>Neuropsychopharmacology</i> , <b>2016</b> , 41, 2502-11	8.7	39
99	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2016</b> , 1, 185-195	18.8	237
98	Antiviral Treatment in Patients with Advanced Hcv Cirrhosis Using Sofosbuvir and Ledipasvir/Daclatasvir with or without Ribavirin - 6 and 12 Month Outcomes Compared to Untreated Patients. <i>Journal of Hepatology</i> , <b>2016</b> , 64, S185-S186	13.4	6
97	Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 44, 957-966	6.1	28
96	Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C. <i>Annals of Hepatology</i> , <b>2016</b> , 15, 512-23	3.1	1
95	Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 533-40	13.4	124

94	Hepatitis delta virus testing, epidemiology and management: a multicentre cross-sectional study of patients in London. <i>Journal of Clinical Virology</i> , <b>2015</b> , 66, 33-7	14.5	23
93	Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK. <i>Clinical Microbiology and Infection</i> , <b>2015</b> , 21, 1033-9	9.5	19
92	Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. <i>Gastroenterology</i> , <b>2015</b> , 149, 1462-70	13.3	178
91	Faldaprevir for the treatment of genotype-1 hepatitis C virus. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2015</b> , 9, 277-88	4.2	2
90	Hope for non-responders with hepatitis C virus and cirrhosis. <i>Lancet Infectious Diseases, The</i> , <b>2015</b> , 15, 363-5	25.5	2
89	Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. <i>Gut</i> , <b>2015</b> , 64, 1824-33	19.2	99
88	Controlling hepatitis C with simeprevir. <i>Lancet Infectious Diseases, The</i> , <b>2015</b> , 15, 2-4	25.5	1
87	Performance of modified-release tacrolimus after conversion in liver transplant patients indicates potentially favorable outcomes in selected cohorts. <i>Liver Transplantation</i> , <b>2015</b> , 21, 29-37	4.5	24
86	Outcomes of pregnancy following liver transplantation: The King's College Hospital experience. <i>Liver Transplantation</i> , <b>2015</b> , 21, 1153-9	4.5	52
85	Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana. <i>Clinical Infectious Diseases</i> , <b>2015</b> , 61, 883-91	11.6	42
84	Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 2599-607	59.2	758
83	Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 2608-17	59.2	613
82	Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infection in the AVIATOR study. <i>Clinical Infectious Diseases</i> , <b>2015</b> , 60, 608-10	11.6	22
81	STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 1246-55	13.4	19
80	Cutaneous side-effects of antihepatitis C treatment: the U.K. experience. <i>British Journal of Dermatology</i> , <b>2015</b> , 172, 292-3	4	3
79	Towards the elimination and eradication of hepatitis B. <i>Journal of Virus Eradication</i> , <b>2015</b> , 1, 4-12	2.8	2
78	Role of liver transplantation in human immunodeficiency virus positive patients. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 12311-21	5.6	10
77	Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: "a flood of opportunity". <i>American Journal of Transplantation</i> , <b>2014</b> , 14, 994-1002	8.7	68

76	ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 1973-82	59.2	754
75	Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 1889-98	59.2	1402
74	Natural history of hepatitis C. <i>Journal of Hepatology</i> , <b>2014</b> , 61, S58-68	13.4	524
73	Recurrent HCV after liver transplantation-mechanisms, assessment and therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2014</b> , 11, 710-21	24.2	26
72	Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 1363-75	6.1	31
71	Patient-important benefits of clearing the hepatitis C virus through treatment: a simulation model. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 1118-26	13.4	18
70	Viral Hepatitis and Hemophilia <b>2014</b> , 263-271		
69	Clinical factors that predict noncirrhotic portal hypertension in HIV-infected patients: a proposed diagnostic algorithm. <i>Journal of Infectious Diseases</i> , <b>2014</b> , 209, 734-8	7	9
68	CXCL10 levels identify individuals with rapid fibrosis at 12 months post-transplant for hepatitis C virus and predict treatment response. <i>Clinical Transplantation</i> , <b>2014</b> , 28, 569-78	3.8	7
67	Forgotten, not neglected: viral hepatitis in resource-limited settings, recall for action. <i>Liver International</i> , <b>2014</b> , 34, 12-5	7.9	12
66	Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 228-34	13.4	80
65	Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C. <i>Gastroenterology</i> , <b>2014</b> , 146, 744-753.e3	13.3	37
64	Liver abnormalities in the immunosuppressed. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2013</b> , 27, 597-618	2.5	1
63	Treatment of chronic hepatitis C virus infection after liver transplantation. <i>Digestive and Liver Disease</i> , <b>2013</b> , 45 Suppl 5, S349-54	3.3	5
62	Hepatitis C treatment: interferon free or interferon free?. <i>Lancet, The</i> , <b>2013</b> , 381, 2063-5	40	1
61	Distinct microRNA profiles are associated with the severity of hepatitis C virus recurrence and acute cellular rejection after liver transplantation. <i>Liver Transplantation</i> , <b>2013</b> , 19, 383-94	4.5	25
60	905 ADHERENCE WITH TELAPREVIR BID vs. q8h DOSING IN TREATMENT-NAÏVE HCV-INFECTED PATIENTS: RESULTS FROM THE PHASE III OPTIMIZE STUDY. <i>Journal of Hepatology</i> , <b>2013</b> , 58, S373	13.4	3
59	Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 37, 659-71	6.1	11

58	Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues. <i>Liver International</i> , <b>2013</b> , 33 Suppl 1, 137-50	7.9	35
57	The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis. <i>Liver International</i> , <b>2013</b> , 33, 53-61	7.9	54
56	The diversity and management of chronic hepatitis B virus infections in the United Kingdom: a wake-up call. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 56, 951-60	11.6	30
55	Maintaining clinical governance when giving telephone advice. <i>Frontline Gastroenterology</i> , <b>2013</b> , 4, 270-273		
54	British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013. <i>HIV Medicine</i> , <b>2013</b> , 14 Suppl 4, 1-71	2.7	27
53	The association of pretransplant ferritin level with waiting list and post-transplant survival. Does ferritin actually predict outcome?. <i>Transplant International</i> , <b>2013</b> , 26, 1070-9	3	9
52	Patient perception of skin-cancer prevention and risk after liver transplantation. <i>Clinical and Experimental Dermatology</i> , <b>2013</b> , 38, 851-6	1.8	10
51	PTH-178 Who Calls the Liver Registrar at King's?. <i>Gut</i> , <b>2013</b> , 62, A283.3-A284	19.2	
50	Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia. <i>Aids</i> , <b>2013</b> , 27, 1443-8	3.5	17
49	Faldaprevir Plus Pegylated Interferon Alfa-2a and Ribavirin in Chronic HCV Genotype-1 Treatment-Naïve Patients: Final Results from STARTVerso1: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial. <i>American Journal of Gastroenterology</i> , <b>2013</b> , 108, S145	0.7	2
48	Development and validation of an efficient in-house real-time reverse transcription polymerase chain reaction assay for the quantitative detection of serum hepatitis delta virus RNA in a diverse South London population. <i>Journal of Virological Methods</i> , <b>2012</b> , 184, 55-62	2.6	14
47	The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. <i>Hepatology</i> , <b>2012</b> , 55, 749-58	11.2	103
46	Interruption of mother-to-infant transmission of hepatitis B: time to include selective antiviral prophylaxis?. <i>Lancet, The</i> , <b>2012</b> , 379, 2019-21	4.0	20
45	UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 647-62	6.1	66
44	Review of the neurological manifestations of hepatitis E infection. <i>Annals of Hepatology</i> , <b>2012</b> , 11, 618-622	3.2	57
43	Hepatitis E--an unexpected problem at home. <i>Scandinavian Journal of Gastroenterology</i> , <b>2012</b> , 47, 253	2.4	13
42	New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye. <i>Gut</i> , <b>2012</b> , 61, 1647-52	19.2	21
41	PMO-178 The significance of viral and serological markers in predicting liver disease severity in e-Ag negative hepatitis b virus infection. <i>Gut</i> , <b>2012</b> , 61, A146.1-A146	19.2	

40	PTU-059 Hepatitis C virus infection abrogates the effect of liver transplantation on NK cell activation. <i>Gut</i> , <b>2012</b> , 61, A208.1-A208	19.2	
39	PTU-016a Functional defects in circulating monocytes may contribute to susceptibility to infection in alcoholic hepatitis. <i>Gut</i> , <b>2012</b> , 61, A189.2-A190	19.2	
38	Massive gastrointestinal bleed in a patient with primary sclerosing cholangitis. <i>Gastroenterology</i> , <b>2011</b> , 140, e7-8	13.3	
37	Telaprevir for previously untreated chronic hepatitis C virus infection. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 2405-16	59.2	2004
36	Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. <i>Hepatology</i> , <b>2011</b> , 54, 1538-46	11.2	43
35	Increasing burden of liver disease in patients with HIV infection. <i>Lancet, The</i> , <b>2011</b> , 377, 1198-209	40	215
34	P47 De-novo antiviral therapy with nucleos(t)ide analogues in real-life patients with chronic hepatitis B infection: comparison of virological responses between lamivudine + adefovir vs entecavir vs tenofovir therapy. <i>Gut</i> , <b>2011</b> , 60, A22-A23	19.2	3
33	P67 Switch to other nucleos(t)ide analogues therapy in chronic hepatitis B cohort on long-term de-novo combination therapy with lamivudine plus adefovir: efficacy and safety. <i>Gut</i> , <b>2011</b> , 60, A31-A31	19.2	
32	P77 A Pharmacist delivered stratified conversion protocol from Hepatitis B Immunoglobulin (HBIG) to tenofovir or entecavir is efficacious, safe and cost-effective for prevention of recurrence of Hepatitis B virus (HBV) in Liver Transplant (LT) recipients. <i>Gut</i> , <b>2011</b> , 60, A35-A36	19.2	
31	The UK experience of liver transplantation in patients receiving opiate replacement therapy. <i>Gut</i> , <b>2011</b> , 60, A58-A59	19.2	
30	P100 Liver transplantation (LT) results in reduced recipient Natural Killer (NK) cell activation with associated down regulation of activating receptors NKp30 and NKp46 but not NKG2D. <i>Gut</i> , <b>2011</b> , 60, A46-A47	19.2	
29	Cholangiocarcinoma complicating recurrent primary sclerosing cholangitis after liver transplantation. <i>Transplant International</i> , <b>2011</b> , 24, e93-6	3	18
28	Liver transplantation in human immunodeficiency virus-positive patients. <i>Liver Transplantation</i> , <b>2011</b> , 17, 881-90	4.5	15
27	Final Results of Open-Label Treatment with Eltrombopag During ENABLE 1: A Study of Eltrombopag As An Adjunct for Antiviral Treatment of Hepatitis C Virus Associated with Thrombocytopenia. <i>Blood</i> , <b>2011</b> , 118, 2232-2232	2.2	4
26	Patient access. How to wipe out a growing killer. <i>The Health Service Journal</i> , <b>2011</b> , 121, 20-2		
25	PTU-060 Primary sclerosing cholangitis post liver transplantation: the impact of inflammatory bowel disease. <i>Gut</i> , <b>2010</b> , 59, A73.1-A73	19.2	
24	Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. <i>Gut</i> , <b>2010</b> , 59, 1245-51	19.2	212
23	Predictors of graft and patient survival in subjects undergoing transplantation for hepatitis C virus infection. <i>Liver Transplantation</i> , <b>2010</b> , 16, 536-7	4.5	2

22	British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. <i>HIV Medicine</i> , <b>2010</b> , 11, 1-30	2.7	63
21	Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 1839-50	59.2	897
20	Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. <i>Gastroenterology</i> , <b>2008</b> , 134, 405-15	13.3	189
19	Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. <i>Liver Transplantation</i> , <b>2008</b> , 14, 861-7	14.5	103
18	Ribavirin considerations in treatment optimization. <i>Antiviral Therapy</i> , <b>2008</b> , 13 Suppl 1, 23-30	1.6	7
17	Ribavirin considerations in treatment optimization. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 23-30	1.6	13
16	A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. <i>Tissue Antigens</i> , <b>2007</b> , 69, 227-35		60
15	The use of drotrecogin alfa (activated) in a patient with recent orthotopic liver transplant. <i>Anaesthesia</i> , <b>2007</b> , 62, 282-5	6.6	8
14	Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin. <i>Transplantation</i> , <b>2007</b> , 84, 180-6	1.8	47
13	Do laparoscopy and intraoperative ultrasound have a role in the assessment of patients with end-stage liver disease and hepatocellular carcinoma for liver transplantation?. <i>Transplantation Proceedings</i> , <b>2007</b> , 39, 1474-6	1.1	7
12	Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation. <i>Liver Transplantation</i> , <b>2006</b> , 12, 827-30	4.5	63
11	Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts. <i>Liver Transplantation</i> , <b>2006</b> , 12, 1496-503	4.5	89
10	Polymorphisms in the T cell regulatory gene cytotoxic T lymphocyte antigen 4 influence the rate of acute rejection after liver transplantation. <i>Gut</i> , <b>2006</b> , 55, 863-8	19.2	24
9	Adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B: a review of the major clinical studies. <i>Journal of Hepatology</i> , <b>2003</b> , 39 Suppl 1, S116-23	13.4	8
8	Hepatitis associated with Chinese herbs. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2002</b> , 14, 559-62	2.2	53
7	Familial primary biliary cirrhosis and autoimmune cholangitis. <i>Digestive and Liver Disease</i> , <b>2002</b> , 34, 50-2	3.3	5
6	Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. <i>Hepatology</i> , <b>2000</b> , 31, 49-53	11.2	198
5	Genetic susceptibility to primary biliary cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , <b>1999</b> , 11, 603-6	2.2	31



- |   |  |      |    |
|---|--|------|----|
| 4 | Treatment of hepatitis C infection. Review underplayed important public health issues. <i>BMJ: British Medical Journal</i> , <b>1999</b> , 319, 450-1          |      | 0  |
| 3 | Alpha interferon for hepatitis C virus infection in haemophilic patients. <i>Haemophilia</i> , <b>1995</b> , 1, 54-8   | 3.3  | 34 |
| 2 | Absence of hepatitis B virus precore mutants in patients with chronic hepatitis B responding to interferon-alpha. <i>Hepatology</i> , <b>1992</b> , 15, 1002-6 | 11.2 | 29 |
| 1 | Hepatitis and Hemophilia486-493  |      |    |